University of California San Francisco

Mattis 144.jpg
Aras N. Mattis, MD, PhD

Assistant Professor, UCSF Department of Pathology

Address

513 Parnassus Avenue, HSW, #516
San Francisco, CA 94143
United States

Phone: 415-514-3062

Biography

Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

Education

Institution Degree Dept or School End Date
University of Illinois Urbana-Champaign PhD Biochemistry 2007
University of Illinois Urbana-Champaign MD Medicine 2007
University of California Berkeley BA Molecular and Cell Biology - Genetics 1998

Board Certifications

American Board of Pathology, Anatomic Pathology

Collaboration Interests

I am interested in:

  • MulticenterClinicalResearch
  • AcademicSenateCommitteeService
  • ProspectiveDonors
  • AcademicCollaboration
  • CompaniesAndEntrepreneurs
  • Press

Clinical Expertise

Liver and Gastrointestinal Pathology

Program Affiliations

UCSF Department of Pathology

California Institute for Regenerative Medicine

Grants and Funding

  • Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIDDK | 2023-06-01 - 2028-05-30 | Role: MPI
  • Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH/NIDDK | 2024-02-01 - 2027-11-30 | Role: PI
  • Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | 2021-06-08 - 2025-03-31 | Role: MPI
  • Regulation of Lipid Metabolism by miR-29a within Hepatocytes | NIH | 2013-09-01 - 2019-07-31 | Role: Principal Investigator

Research Narrative

Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

Research Interests

Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte

Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 53
  1. Fluoride-related changes in the fetal cord blood proteome; a pilot study.
    Tuomivaara ST, Fisher SJ, Hall SC, Goin DE, Mattis AN, Den Besten PK| | PubMed
  2. Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas.
    Hsu BY, Driscoll J, Human Cholangiocarcinogenesis Project, Tateno C, Mattis AN, Kelley RK, Willenbring H| | PubMed
  3. MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.
    Lewis KA, Stroebel BM, Zhang L, Aouizerat B, Mattis AN, Flowers E| | PubMed
  4. AMPK stimulation inhibits YAP/TAZ signaling to ameliorate hepatic fibrosis.
    Shihan MH, Sharma S, Cable C, Prathigudupu V, Chen A, Mattis AN, Chen JY| | PubMed
  5. Fluoride-related changes in the fetal cord blood proteome; a pilot study.
    Tuomivaara ST, Goin DE, Fisher SJ, Hall SC, Mattis AN, Den Besten PK| | PubMed
  6. MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.
    Lewis KA, Stroebel B, Zhang L, Aouizerat B, Mattis A, Flowers E| | PubMed
  7. Hyperpolarized [1-13 C] pyruvate MRSI to detect metabolic changes in liver in a methionine and choline-deficient diet rat model of fatty liver disease.
    Piraquive Agudelo J, Kim Y, Agarwal S, Sriram R, Bok R, Kurhanewicz J, Mattis AN, Maher JJ, von Morze C, Ohliger MA| | PubMed
  8. Group 2 innate lymphoid cells constrain type 3/17 lymphocytes in shared stromal niches to restrict liver fibrosis.
    Sbierski-Kind J, Cautivo KM, Wagner JC, Dahlgren MW, Nilsson J, Krasilnikov M, Mroz NM, Lizama CO, Gan AL, Matatia PR, Taruselli MT, Chang AA, Caryotakis S, O'Leary CE, Kotas M, Mattis AN, Peng T, Locksley RM, Molofsky AB| | PubMed
  9. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
  10. DNA content abnormality frequently develops in the right/proximal colon in patients with primary sclerosing cholangitis and inflammatory bowel disease and is highly predictive of subsequent detection of dysplasia.
    Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
  11. Self-Assembled Matrigel-Free iPSC-Derived Liver Organoids Demonstrate Wide-Ranging Highly Differentiated Liver Functions.
    Weng Y, Han S, Sekyi MT, Su T, Mattis AN, Chang TT| | PubMed
  12. Fundic Gland Polyps Lack DNA Content Abnormality Characteristic of Other Adenomatous Precursor Lesions in the Gastrointestinal Tract.
    Akanuma N, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
  13. Transient expression of factor VIII and a chronic high-fat diet induces ER stress and late hepatocyte oncogenesis.
    Pierce GF, Mattis AN| | PubMed
  14. Targeting acid ceramidase ameliorates fibrosis in mouse models of non-alcoholic steatohepatitis.
    Yu A, Cable C, Sharma S, Shihan MH, Mattis AN, Mileva I, Hannun YA, Duwaerts CC, Chen JY| | PubMed
  15. Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease.
    Muñoz A, Theusch E, Kuang YL, Nalula G, Peaslee C, Dorlhiac G, Landry MP, Streets A, Krauss RM, Iribarren C, Mattis AN, Medina MW| | PubMed
  16. Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review.
    Bogliotti Y, Vander Roest M, Mattis AN, Gish RG, Peltz G, Anwyl R, Kivlighn S, Schuur ER| | PubMed
  17. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
    Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S, Russell CB, Kim B, Lawal A, Rangarajan S, Lester W, Bunting S, Pierce GF, Pasi KJ, Wong WY| | PubMed
  18. Nonampullary Duodenal Adenomas in Familial Adenomatous Polyposis and Sporadic Patients Lack the DNA Content Abnormality That Is Characteristic of the Adenoma-Carcinoma Sequence Involved in the Development of Other Gastrointestinal Malignancies.
    Mohammed N, Rabinovitch PS, Wang D, Kovári BP, Mattis AN, Lauwers GY, Choi WT| | PubMed
  19. Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation.
    Peaslee C, Esteva-Font C, Su T, Munoz-Howell A, Duwaerts CC, Liu Z, Rao S, Liu K, Medina M, Sneddon JB, Maher JJ, Mattis AN| | PubMed
  20. Gastric Intestinal Metaplasia in Mucosa Adjacent to Gastric Cancers Is Rarely Associated With the Aneuploidy That Is Characteristic of Gastric Dysplasia or Cancer.
    Zhang R, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
  21. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
    Bowman CJ, Zhang R, Balitzer D, Wang D, Rabinovitch PS, Kovári BP, Mattis AN, Kakar S, Lauwers GY, Choi WT| | PubMed
  22. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile.
    Duwaerts CC, Le Guillou D, Her CL, Phillips NJ, Willenbring H, Mattis AN, Maher JJ| | PubMed
  23. Non-conventional dysplasia in inflammatory bowel disease is more frequently associated with advanced neoplasia and aneuploidy than conventional dysplasia.
    Lee H, Rabinovitch PS, Mattis AN, Lauwers GY, Choi WT| | PubMed
  24. Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1α.
    Duwaerts CC, Siao K, Soon RK, Her C, Iwawaki T, Kohno K, Mattis AN, Maher JJ| | PubMed
  25. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice.
    Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, Ferreira DDS, Ma HY, Duwaerts CC, Espanol-Suner R, Wei L, Newcomb B, Mileva I, Canals D, Hannun YA, Chung RT, Mattis AN, Fuchs BC, Tager AM, Yimlamai D, Weaver VM, Mullen AC, Sheppard D, Chen JY| | PubMed
  26. Ly6cLo non-classical monocytes promote resolution of rhesus rotavirus-mediated perinatal hepatic inflammation.
    Alkhani A, Levy CS, Tsui M, Rosenberg KA, Polovina K, Mattis AN, Mack M, Van Dyken S, Wang BM, Maher JJ, Nijagal A| | PubMed
  27. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW, Rabinovitch PS, Wang D, Mattis AN, Ferrell LD, Choi WT| | PubMed
  28. DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.
    Lee H, Rabinovitch PS, Mattis AN, Kakar S, Choi WT| | PubMed
  29. De novo somatic mutations and KRAS amplification are associated with cholangiocarcinoma in a patient with a history of choledochal cyst.
    Schwab ME, Song H, Mattis A, Phelps A, Vu LT, Huang FW, Nijagal A| | PubMed
  30. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
    Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ| | PubMed
  31. Diagnosis, risk stratification, and management of ampullary dysplasia by DNA flow cytometric analysis of paraffin-embedded tissue.
    Wen KW, Kim GE, Rabinovitch PS, Wang D, Mattis AN, Choi WT| | PubMed
  32. Evaluation of commonly used ectoderm markers in iPSC trilineage differentiation.
    Kuang YL, Munoz A, Nalula G, Santostefano KE, Sanghez V, Sanchez G, Terada N, Mattis AN, Iacovino M, Iribarren C, Krauss RM, Medina MW| | PubMed
  33. Utility of DNA Flow Cytometric Analysis of Paraffin-embedded Tissue in the Risk Stratification and Management of 'Indefinite for dysplasia' in Patients With Inflammatory Bowel Disease.
    Wen KW, Rabinovitch PS, Wang D, Huang D, Mattis AN, Choi WT| | PubMed
  34. Depletion of murine fetal hematopoietic stem cells with c-Kit receptor and CD47 blockade improves neonatal engraftment.
    Witt RG, Wang B, Nguyen QH, Eikani C, Mattis AN, MacKenzie TC| | PubMed
  35. DNA content analysis of colorectal serrated lesions detects an aneuploid subset of inflammatory bowel disease-associated serrated epithelial change and traditional serrated adenomas.
    Choi WT, Wen KW, Rabinovitch PS, Huang D, Mattis AN, Gill RM| | PubMed
  36. Use of DNA flow cytometry in the diagnosis, risk stratification, and management of gastric epithelial dysplasia.
    Wen KW, Rabinovitch PS, Huang D, Mattis AN, Lauwers GY, Choi WT| | PubMed
  37. De novo formation of the biliary system by TGFβ-mediated hepatocyte transdifferentiation.
    Schaub JR, Huppert KA, Kurial SNT, Hsu BY, Cast AE, Donnelly B, Karns RA, Chen F, Rezvani M, Luu HY, Mattis AN, Rougemont AL, Rosenthal P, Huppert SS, Willenbring H| | PubMed
  38. CD18 deficiency improves liver injury in the MCD model of steatohepatitis.
    Pierce AA, Duwaerts CC, Siao K, Mattis AN, Goodsell A, Baron JL, Maher JJ| | PubMed
  39. Association of Aneuploidy and Flat Dysplasia With Development of High-Grade Dysplasia or Colorectal Cancer in Patients With Inflammatory Bowel Disease.
    Tsai JH, Rabinovitch PS, Huang D, Small T, Mattis AN, Kakar S, Choi WT| | PubMed
  40. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
    Choi WT, Tsai JH, Rabinovitch PS, Small T, Huang D, Mattis AN, Kakar S| | PubMed
  41. Diffusion-weighted imaging of hyperpolarized [13 C]urea in mouse liver.
    Marco-Rius I, Gordon JW, Mattis AN, Bok R, Delos Santos R, Sukumar S, Larson PEZ, Vigneron DB, Ohliger MA| | PubMed
  42. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models.
    Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR| | PubMed
  43. Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5.
    Frascoli M, Jeanty C, Fleck S, Moradi PW, Keating S, Mattis AN, Tang Q, MacKenzie TC| | PubMed
  44. Human stem cells from single blastomeres reveal pathways of embryonic or trophoblast fate specification.
    Zdravkovic T, Nazor KL, Larocque N, Gormley M, Donne M, Hunkapillar N, Giritharan G, Bernstein HS, Wei G, Hebrok M, Zeng X, Genbacev O, Mattis A, McMaster MT, Krtolica A, Valbuena D, Simón C, Laurent LC, Loring JF, Fisher SJ| | PubMed
  45. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver.
    Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E, Koliwad S, Lim LP, Maher JJ, Raffai RL, Willenbring H| | PubMed
  46. Mouse liver repopulation with hepatocytes generated from human fibroblasts.
    Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S| | PubMed
  47. A ZFN/piggyBac step closer to autologous liver cell therapy.
    Mattis AN, Willenbring H| | PubMed
  48. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver.
    Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL| | PubMed
  49. Clinical diagnosis of segmental arterial mediolysis: differentiation from vasculitis and other mimics.
    Baker-LePain JC, Stone DH, Mattis AN, Nakamura MC, Fye KH| | PubMed
  50. Purification and characterization of bacteriophage P22 Xis protein.
    Mattis AN, Gumport RI, Gardner JF| | PubMed
  51. IntDOT interactions with core- and arm-type sites of the conjugative transposon CTnDOT.
    Dichiara JM, Mattis AN, Gardner JF| | PubMed
  52. Integration host factor: putting a twist on protein-DNA recognition.
    Lynch TW, Read EK, Mattis AN, Gardner JF, Rice PA| | PubMed
  53. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast.
    Werner M, Mattis A, Aubele M, Cummings M, Zitzelsberger H, Hutzler P, Höfler H| | PubMed